CN116969863A - Method for preparing Sha Kuba curved intermediate by utilizing micro-channel method - Google Patents
Method for preparing Sha Kuba curved intermediate by utilizing micro-channel method Download PDFInfo
- Publication number
- CN116969863A CN116969863A CN202310947198.3A CN202310947198A CN116969863A CN 116969863 A CN116969863 A CN 116969863A CN 202310947198 A CN202310947198 A CN 202310947198A CN 116969863 A CN116969863 A CN 116969863A
- Authority
- CN
- China
- Prior art keywords
- compound
- microchannel
- solution
- sodium
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 36
- 150000001875 compounds Chemical class 0.000 claims abstract description 47
- 238000006243 chemical reaction Methods 0.000 claims abstract description 39
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 21
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 19
- 230000035484 reaction time Effects 0.000 claims abstract description 13
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims abstract description 10
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims abstract description 10
- 239000003513 alkali Substances 0.000 claims abstract 2
- 239000000463 material Substances 0.000 claims description 44
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 21
- PYNXFZCZUAOOQC-UTKZUKDTSA-N sacubitril Chemical compound C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC(O)=O)=CC=C1C1=CC=CC=C1 PYNXFZCZUAOOQC-UTKZUKDTSA-N 0.000 claims description 21
- 229960003953 sacubitril Drugs 0.000 claims description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
- 239000002585 base Substances 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 claims description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 6
- 235000017550 sodium carbonate Nutrition 0.000 claims description 6
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 claims description 6
- -1 potassium alkoxide Chemical class 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- SYBYTAAJFKOIEJ-UHFFFAOYSA-N 3-Methylbutan-2-one Chemical compound CC(C)C(C)=O SYBYTAAJFKOIEJ-UHFFFAOYSA-N 0.000 claims description 4
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 claims description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 claims description 4
- 239000007800 oxidant agent Substances 0.000 claims description 4
- 239000003444 phase transfer catalyst Substances 0.000 claims description 4
- 238000012805 post-processing Methods 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 4
- ZNOKGRXACCSDPY-UHFFFAOYSA-N tungsten trioxide Chemical compound O=[W](=O)=O ZNOKGRXACCSDPY-UHFFFAOYSA-N 0.000 claims description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical group [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 claims description 3
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 claims description 3
- 239000012312 sodium hydride Substances 0.000 claims description 3
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 3
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 3
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 3
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 claims description 2
- JHWIEAWILPSRMU-UHFFFAOYSA-N 2-methyl-3-pyrimidin-4-ylpropanoic acid Chemical compound OC(=O)C(C)CC1=CC=NC=N1 JHWIEAWILPSRMU-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 239000005708 Sodium hypochlorite Substances 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 2
- 239000012286 potassium permanganate Substances 0.000 claims description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 229910001882 dioxygen Inorganic materials 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 6
- 239000000047 product Substances 0.000 abstract description 5
- 239000006227 byproduct Substances 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 description 40
- 239000000243 solution Substances 0.000 description 38
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- 238000003756 stirring Methods 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 13
- 239000007864 aqueous solution Substances 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 12
- 206010019280 Heart failures Diseases 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229940126905 angiotensin receptor-neprilysin inhibitor Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940100334 sacubitril / valsartan Drugs 0.000 description 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 2
- 229960004699 valsartan Drugs 0.000 description 2
- 101001053401 Arabidopsis thaliana Acid beta-fructofuranosidase 3, vacuolar Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229940100321 entresto Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- ZASXKEGREHRXDL-CAWNUZPDSA-H hexasodium;4-[[(2s,4r)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate;(2s)-3-methyl-2-[pentanoyl-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]amino]butanoate;pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC([O-])=O)=CC=C1C1=CC=CC=C1.C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC([O-])=O)=CC=C1C1=CC=CC=C1.C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C([O-])=O)=CC=C1C1=CC=CC=C1C1=NN=N[N-]1.C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C([O-])=O)=CC=C1C1=CC=CC=C1C1=NN=N[N-]1 ZASXKEGREHRXDL-CAWNUZPDSA-H 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/70—Sulfur atoms
- C07D277/74—Sulfur atoms substituted by carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/70—Sulfur atoms
- C07D277/76—Sulfur atoms attached to a second hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
技术领域Technical field
本发明属于有机合成领域,特别是涉及有机药物合成技术领域,更为具体的说是涉及一种利用微通道法制备沙库巴曲中间体的方法。The invention belongs to the field of organic synthesis, in particular to the technical field of organic drug synthesis, and more specifically to a method for preparing sacubitril intermediates using a microchannel method.
背景技术Background technique
心力衰竭已经成为严重危害人类健康的全球性公共卫生问题,是心血管疾病发生发展的终末阶段,其发病率、再住院率及死亡率都在逐年不断增长,这使得进一步开发更为有效的新型治疗心力衰竭的药物迫在眉睫,而具有血管紧张素受体-脑啡肽酶抑制剂双重作用机制的沙库巴曲/缬沙坦的上市为心衰患者的治疗带来了新的变革。Heart failure has become a global public health problem that seriously endangers human health. It is the final stage of the development of cardiovascular diseases. Its incidence, rehospitalization rate and mortality rate are increasing year by year, which makes further development of more effective New drugs for the treatment of heart failure are urgent, and the launch of sacubitril/valsartan, which has a dual action mechanism of angiotensin receptor-neprilysin inhibitor, has brought new changes to the treatment of heart failure patients.
沙库巴曲/缬沙坦(Entresto)是由诺华公司开发的双效血管紧张素受体-脑啡肽酶抑制剂,临床上可用于高血压和心力衰竭的治疗。该药由作用于脑啡肽酶的沙库巴曲和作用于肾素-血管紧张素-醛固酮系统的缬沙坦组成,可有效改善心力衰竭症状,降低血压并可积极改善肾功能,是一种理想的心力衰竭治疗药物。Sacubitril/valsartan (Entresto) is a dual-effect angiotensin receptor-neprilysin inhibitor developed by Novartis and can be used clinically for the treatment of hypertension and heart failure. The drug consists of sacubitril, which acts on neprilysin, and valsartan, which acts on the renin-angiotensin-aldosterone system. It can effectively improve symptoms of heart failure, lower blood pressure and actively improve kidney function. It is a drug that An ideal drug for the treatment of heart failure.
由于缬沙坦的合成工艺比较成熟,因此本领域技术人员的研究焦点集中在沙库巴曲部分的合成优化中。Since the synthesis process of valsartan is relatively mature, the research focus of those skilled in the art is on the optimization of the synthesis of the sacubitril part.
沙库巴曲(Sacubitril),化学名为4-(((2S,4R)-1-([1,1'-联苯]-4-基)-5-乙氧基-4-甲基-5-氧代丙烷-2-基)氨基)-4-氧代丁酸,其结构如下:Sacubitril, chemical name is 4-(((2S,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-methyl- 5-Oxopropan-2-yl)amino)-4-oxobutyric acid, its structure is as follows:
化合物I是制备沙库巴曲药物的重要中间体,Compound I is an important intermediate for the preparation of sacubitril drugs.
在原研专利US5217996中公开了沙库巴曲的制备方法,其合成路线如下:The preparation method of sacubitril is disclosed in the original patent US5217996, and its synthesis route is as follows:
在该合成路线中化合物I是由化合物II与磷叶立德试剂发生反应制备而成,其中磷叶立德试剂的结构如式a所示,In this synthetic route, compound I is prepared by reacting compound II with a phosphorus ylide reagent, where the structure of the phosphorus ylide reagent is shown in formula a,
目前现有技术中普遍采用这一方式通过经典的Wittig反应制备化合物I。但是,该方法下化合物I的收率仅为78%,较低的反应收率不仅造成手性醇原料的浪费,而且也使得沙库巴曲工业化合成的成本居高不下。This method is currently commonly used in the prior art to prepare compound I through the classic Wittig reaction. However, the yield of compound I under this method is only 78%. The low reaction yield not only causes a waste of chiral alcohol raw materials, but also makes the cost of industrial synthesis of sacubitril high.
微通道反应器具有高比表面积和富有规律的层流特征,反应物在微通道反应器内反应时,能够连续不断参与后续反应,从而获得高效时空产率。同时,相比于传统的制备工艺,微通道反应器还具有传质速率快、停留时间短,重复性好,便于自动化控制等优势。Microchannel reactors have high specific surface area and regular laminar flow characteristics. When reactants react in the microchannel reactor, they can continuously participate in subsequent reactions, thereby obtaining high space-time yields. At the same time, compared with traditional preparation processes, microchannel reactors also have the advantages of fast mass transfer rate, short residence time, good repeatability, and easy automatic control.
目前,尚未看到采用微通道反应器制备沙库巴曲中间体化合物I的技术方案公开。At present, no technical solution for preparing sacubitril intermediate compound I using a microchannel reactor has been disclosed.
发明内容Contents of the invention
本发明所要解决的技术问题是提供一种利用微通道法制备沙库巴曲中间体的方法,从而能够改善沙库巴曲中间体合成工艺,实现低成本、高收率、高安全性以及对环境友好的技术效果。The technical problem to be solved by the present invention is to provide a method for preparing sacubitril intermediate using microchannel method, thereby improving the synthesis process of sacubitril intermediate and achieving low cost, high yield, high safety and environmental protection. Environmentally friendly technical effects.
为了解决上述技术问题,本发明公开了一种利用微通道法制备沙库巴曲中间体的方法,包括以下步骤:In order to solve the above technical problems, the present invention discloses a method for preparing sacubitril intermediate using microchannel method, which includes the following steps:
(1)将化合物II溶解于溶剂中,制备得到物料A溶液;(1) Dissolve compound II in a solvent to prepare a solution of material A;
(2)将化合物III溶解于溶剂中,制备得到物料B溶液;(2) Dissolve compound III in a solvent to prepare a solution of material B;
(3)将碱溶解于溶剂中,制备得到物料C溶液;(3) Dissolve the base in the solvent to prepare a solution of material C;
(4)将物料A溶液、物料B溶液和物料C溶液分别按照预设的流速泵入微通道反应器中,微通道反应器换热器温度设定在-100~-50℃之间,物料在微通道反应器内的停留反应时间设定在60~300s之间;(4) Pump material A solution, material B solution and material C solution into the microchannel reactor respectively according to the preset flow rate. The heat exchanger temperature of the microchannel reactor is set between -100~-50°C. The residence reaction time in the microchannel reactor is set between 60 and 300 seconds;
从微通道反应器出口处获得含有化合物I的产物;然后经后处理得到化合物I;这里的后处理是指化合物的纯化、精化等处理步骤,包括但不限于猝灭、分离、萃取、洗涤、浓缩、重结晶;The product containing compound I is obtained from the outlet of the microchannel reactor; then compound I is obtained through post-processing; post-processing here refers to the purification, refinement and other processing steps of the compound, including but not limited to quenching, separation, extraction, and washing. , concentration, recrystallization;
该反应的合成路线如下:The synthesis route of this reaction is as follows:
其中,R选自中的任意一种。Among them, R is selected from any of them.
进一步地,所述碱为氢化钠、LiHMDS、NaHMDS、甲醇钠、乙醇钠、丁基锂、叔丁醇钾、叔丁醇钠或LDA中的一种。Further, the base is one of sodium hydride, LiHMDS, NaHMDS, sodium methoxide, sodium ethoxide, butyllithium, potassium tert-butoxide, sodium tert-butoxide or LDA.
进一步地,所述化合物II与化合物III、碱的摩尔比为1:(1~1.5):(1~1.5)。Further, the molar ratio of compound II to compound III and base is 1: (1-1.5): (1-1.5).
进一步地,各步骤中溶剂相同,且均选自四氢呋喃、甲苯、甲基叔丁基醚、二氧六环、乙酸乙酯、丙酮或甲基异丙基酮中的任意一种或几种。Furthermore, the solvents in each step are the same and are selected from any one or more of tetrahydrofuran, toluene, methyl tert-butyl ether, dioxane, ethyl acetate, acetone or methyl isopropyl ketone.
进一步地,所述反应温度为-90~-60℃,可以但不局限于-90℃、-85℃、-80℃、-75℃、-70℃、-65℃或-60℃,为了获得更好的效果,反应温度优选为-70℃。Further, the reaction temperature is -90~-60°C, which can be but is not limited to -90°C, -85°C, -80°C, -75°C, -70°C, -65°C or -60°C, in order to obtain For better effect, the reaction temperature is preferably -70°C.
进一步地,微通道反应器内物料停留反应时间优选设定为80~260s。Furthermore, the residence reaction time of materials in the microchannel reactor is preferably set to 80 to 260 s.
进一步地,物料A、物料B、物料C溶液在微通道反应器中的流速优选为:物料A溶液的流速为5ml/min;物料B溶液的流速为7.5ml/min;物料C溶液的流速为4ml/min。Further, the flow rate of the material A, material B, and material C solutions in the microchannel reactor is preferably: the flow rate of the material A solution is 5 ml/min; the flow rate of the material B solution is 7.5 ml/min; the flow rate of the material C solution is 4ml/min.
进一步地,在本发明中化合物III的合成包括以下步骤:Further, in the present invention, the synthesis of compound III includes the following steps:
(1)将化合物V和化合物VI在碱、相转移催化剂存在下反应得到化合物IV;(1) Compound V is reacted with compound VI in the presence of a base and a phase transfer catalyst to obtain compound IV;
(2)在催化剂存在下,将化合物IV用氧化剂氧化得到化合物III,(2) In the presence of a catalyst, compound IV is oxidized with an oxidizing agent to obtain compound III,
具体合成路线如下:The specific synthesis route is as follows:
其中,R选自中的任意一种。Among them, R is selected from any of them.
进一步地,在步骤(1)中相转移催化剂为四丁基溴化铵、四丁基氯化铵、四丁基硫酸氢铵、苄基三乙基氯化铵或18冠6醚中的一种。Further, in step (1), the phase transfer catalyst is one of tetrabutylammonium bromide, tetrabutylammonium chloride, tetrabutylammonium bisulfate, benzyltriethylammonium chloride or 18-crown 6 ether. kind.
进一步地,在步骤(1)中碱为碳酸钠、碳酸钾、碳酸氢钠、碳酸氢钾、氢氧化钠或氢氧化钾中的一种。Further, in step (1), the base is one of sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide or potassium hydroxide.
进一步地,步骤(1)中的溶剂为二甲基亚砜、N,N-二甲基甲酰胺、甲醇、异丙醇或N-甲基吡咯烷酮中的一种或多种。Further, the solvent in step (1) is one or more of dimethyl sulfoxide, N,N-dimethylformamide, methanol, isopropyl alcohol or N-methylpyrrolidone.
进一步地,步骤(1)中的反应温度为80~140℃,可以但不局限于80℃、85℃、90℃、95℃、100℃、105℃、110℃、115℃、120℃、125℃、130℃、135℃或140℃,为了获得更好的效果,反应温度优选为125℃。Further, the reaction temperature in step (1) is 80-140°C, which can be but is not limited to 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C ℃, 130 ℃, 135 ℃ or 140 ℃, in order to obtain better results, the reaction temperature is preferably 125 ℃.
进一步地,在步骤(2)中催化剂为七钼酸铵四水合物、磷钼酸或三氧化钨中的一种。Further, in step (2), the catalyst is one of ammonium heptamolybdate tetrahydrate, phosphomolybdic acid or tungsten trioxide.
进一步地,步骤(2)中的氧化剂为过氧化氢、次氯酸钠、高锰酸钾、过硼酸钾、重铬酸钠或间氯过氧苯甲酸中的一种。Further, the oxidizing agent in step (2) is one of hydrogen peroxide, sodium hypochlorite, potassium permanganate, potassium perborate, sodium dichromate or meta-chloroperoxybenzoic acid.
进一步地,步骤(2)中的溶剂为二甲基亚砜、N,N-二甲基甲酰胺、乙腈或N-甲基吡咯烷酮中的一种或多种。Further, the solvent in step (2) is one or more of dimethyl sulfoxide, N,N-dimethylformamide, acetonitrile or N-methylpyrrolidone.
进一步地,步骤(2)中的反应温度为-10~40℃,可以但不局限于-10℃、-5℃、0℃、5℃、10℃、15℃、20℃、25℃、30℃、35℃或40℃,为了获得更好的效果,反应温度优选为5℃。Further, the reaction temperature in step (2) is -10~40°C, which can be but is not limited to -10°C, -5°C, 0°C, 5°C, 10°C, 15°C, 20°C, 25°C, 30°C ℃, 35 ℃ or 40 ℃, in order to obtain better results, the reaction temperature is preferably 5 ℃.
本发明通过微通道反应器将化合物II与化合物III在碱存在下反应得到目标化合物I。通过对微通道反应器换热器温度和反应时间的控制,能够有效提高反应效率,降低反应副产物的产生,制备效率和产物纯度得到显著提升,从而有效解决了现有技术中反应时间长,副产物多,对设备要求高、收率和纯度低等难题。In the present invention, the target compound I is obtained by reacting compound II and compound III in the presence of a base through a microchannel reactor. By controlling the temperature and reaction time of the microchannel reactor heat exchanger, the reaction efficiency can be effectively improved, the production of reaction by-products can be reduced, and the preparation efficiency and product purity can be significantly improved, thereby effectively solving the problem of long reaction times in the existing technology. There are many by-products, high equipment requirements, low yield and purity and other problems.
本发明通过流速、温度、反应时间,精确控制物料反应程序,大幅缩短了反应时间,整个反应安全性高、成本低、后处理简单,产物化合物I的收率和纯度较高,是一种适合于工业化大规模生产的高效制备新方法。The present invention accurately controls the material reaction procedure through flow rate, temperature and reaction time, greatly shortening the reaction time. The entire reaction has high safety, low cost, simple post-processing, and the yield and purity of the product compound I are high. It is a suitable A new efficient preparation method for industrial large-scale production.
具体实施方式Detailed ways
为了更好的理解本发明,下面我们结合具体的实施例对本发明进行进一步的阐述。In order to better understand the present invention, we will further elaborate the present invention with reference to specific embodiments.
除非有特殊说明,在本发明实施例中所用试剂均为普通市售产品。Unless otherwise specified, the reagents used in the examples of the present invention are common commercially available products.
实施例1Example 1
(1)化合物IV-1的合成(1) Synthesis of compound IV-1
氮气保护下,向反应容器中加入化合物V(10g,73mmol)、化合物VI-1(14.3g,80.3mmol)和100ml二甲基亚砜,搅拌溶解。再加入四丁基溴化铵(1.2g,3.7mmol)和碳酸氢钠(12.3g,146mmol),将反应混合物在125℃下进行反应。反应结束后,将反应混合物降温至20℃,加入200mL甲基叔丁基醚和200mL饱和NaHCO3水溶液。分离有机层,并用100mL甲基叔丁基醚洗涤水层。再用100mL饱和NaHCO3水溶液洗涤合并的有机相,用Na2SO4干燥后,浓缩有机相,得到化合物IV-1,收率96.5%,纯度99.4%。Under nitrogen protection, add compound V (10g, 73mmol), compound VI-1 (14.3g, 80.3mmol) and 100ml dimethyl sulfoxide into the reaction vessel, stir and dissolve. Tetrabutylammonium bromide (1.2g, 3.7mmol) and sodium bicarbonate (12.3g, 146mmol) were then added, and the reaction mixture was reacted at 125°C. After the reaction is completed, the reaction mixture is cooled to 20°C, and 200 mL of methyl tert-butyl ether and 200 mL of saturated NaHCO 3 aqueous solution are added. The organic layer was separated and the aqueous layer was washed with 100 mL of methyl tert-butyl ether. The combined organic phases were washed with 100 mL of saturated NaHCO 3 aqueous solution, dried over Na 2 SO 4 , and concentrated to obtain compound IV-1 with a yield of 96.5% and a purity of 99.4%.
(2)化合物III-1的合成(2) Synthesis of compound III-1
向反应容器中加入化合物IV-1(10g,36mmol)和100mL二甲基亚砜,搅拌溶解。将反应溶液冷却至5℃,然后加入七钼酸铵四水合物(0.9g,0.72mmol)和30%过氧化氢(16.3g,144mmol),将反应混合物在5℃下进行反应。反应结束后,将反应混合物升温至20℃,加入50mL二甲基亚砜和100mL饱和NaHCO3水溶液。分离有机相,用50mL饱和NaHCO3水溶液洗涤,用Na2SO4干燥后,浓缩有机相,再用异丙醇重结晶,得到化合物III-1,收率92.7%,纯度99.1%。Add compound IV-1 (10 g, 36 mmol) and 100 mL dimethyl sulfoxide to the reaction vessel, and stir to dissolve. The reaction solution was cooled to 5°C, then ammonium heptamolybdate tetrahydrate (0.9g, 0.72mmol) and 30% hydrogen peroxide (16.3g, 144mmol) were added, and the reaction mixture was reacted at 5°C. After the reaction is completed, the reaction mixture is heated to 20°C, and 50 mL of dimethyl sulfoxide and 100 mL of saturated NaHCO 3 aqueous solution are added. Separate the organic phase, wash with 50 mL saturated NaHCO 3 aqueous solution, dry with Na 2 SO 4 , concentrate the organic phase, and then recrystallize with isopropyl alcohol to obtain compound III-1 with a yield of 92.7% and a purity of 99.1%.
实施例2Example 2
(1)化合物IV-2的合成(1) Synthesis of compound IV-2
氮气保护下,向反应容器中加入化合物V(10g,73mmol)、化合物VI-2(13.4g,80.3mmol)和100ml N,N-二甲基甲酰胺,搅拌溶解。再加入四丁基氯化铵(1g,3.7mmol)和碳酸钠(15.5g,146mmol),将反应混合物在140℃下进行反应。反应结束后,将反应混合物降温至20℃,加入200mL甲基叔丁基醚和200mL饱和NaHCO3水溶液。分离有机层,并用100mL甲基叔丁基醚洗涤水层。再用100mL饱和NaHCO3水溶液洗涤合并的有机相,用Na2SO4干燥后,浓缩有机相,得到化合物IV-2,收率94.1%,纯度99.2%。Under nitrogen protection, add compound V (10g, 73mmol), compound VI-2 (13.4g, 80.3mmol) and 100ml N,N-dimethylformamide into the reaction vessel, stir and dissolve. Tetrabutylammonium chloride (1g, 3.7mmol) and sodium carbonate (15.5g, 146mmol) were then added, and the reaction mixture was reacted at 140°C. After the reaction is completed, the reaction mixture is cooled to 20°C, and 200 mL of methyl tert-butyl ether and 200 mL of saturated NaHCO 3 aqueous solution are added. The organic layer was separated and the aqueous layer was washed with 100 mL of methyl tert-butyl ether. The combined organic phases were washed with 100 mL of saturated NaHCO 3 aqueous solution, dried over Na 2 SO 4 , and concentrated to obtain compound IV-2 with a yield of 94.1% and a purity of 99.2%.
(2)化合物III-2的合成(2) Synthesis of compound III-2
向反应容器中加入化合物IV-2(9.6g,36mmol)和100mL乙腈,搅拌溶解。将反应溶液冷却至-10℃,然后加入磷钼酸(1.3g,0.72mmol)和30%过氧化氢(16.3g,144mmol),将反应混合物在-10℃下进行反应。反应结束后,将反应混合物升温至20℃,加入50mL乙腈和100mL饱和NaHCO3水溶液。分离有机相,用50mL饱和NaHCO3水溶液洗涤,用Na2SO4干燥后,浓缩有机相,再用异丙醇重结晶,得到化合物III-2,收率89.6%,纯度99.2%。Add compound IV-2 (9.6 g, 36 mmol) and 100 mL acetonitrile to the reaction vessel, and stir to dissolve. The reaction solution was cooled to -10°C, then phosphomolybdic acid (1.3g, 0.72mmol) and 30% hydrogen peroxide (16.3g, 144mmol) were added, and the reaction mixture was reacted at -10°C. After the reaction is completed, the reaction mixture is heated to 20°C, and 50 mL of acetonitrile and 100 mL of saturated NaHCO 3 aqueous solution are added. Separate the organic phase, wash with 50 mL saturated NaHCO 3 aqueous solution, dry with Na 2 SO 4 , concentrate the organic phase, and then recrystallize with isopropyl alcohol to obtain compound III-2 with a yield of 89.6% and a purity of 99.2%.
实施例3Example 3
(1)化合物IV-3的合成(1) Synthesis of compound IV-3
氮气保护下,向反应容器中加入化合物V(10g,73mmol)、化合物VI-3(10.6g,80.3mmol)和100ml甲醇,搅拌溶解。再加入苄基三乙基氯化铵(0.84g,3.7mmol)和氢氧化钠(5.8g,146mmol),将反应混合物在80℃下进行反应。反应结束后,将反应混合物降温至20℃,加入200mL甲基叔丁基醚和200mL饱和NaHCO3水溶液。分离有机层,并用100mL甲基叔丁基醚洗涤水层。再用100mL饱和NaHCO3水溶液洗涤合并的有机相,用Na2SO4干燥后,浓缩有机相,得到化合物IV-3,收率91.8%,纯度99.3%。Under nitrogen protection, add compound V (10g, 73mmol), compound VI-3 (10.6g, 80.3mmol) and 100ml methanol into the reaction vessel, stir and dissolve. Benzyltriethylammonium chloride (0.84g, 3.7mmol) and sodium hydroxide (5.8g, 146mmol) were then added, and the reaction mixture was reacted at 80°C. After the reaction is completed, the reaction mixture is cooled to 20°C, and 200 mL of methyl tert-butyl ether and 200 mL of saturated NaHCO 3 aqueous solution are added. The organic layer was separated and the aqueous layer was washed with 100 mL of methyl tert-butyl ether. The combined organic phases were then washed with 100 mL of saturated NaHCO 3 aqueous solution, dried over Na 2 SO 4 , and the organic phase was concentrated to obtain compound IV-3 with a yield of 91.8% and a purity of 99.3%.
(2)化合物III-3的合成(2) Synthesis of compound III-3
向反应容器中加入化合物IV-3(8.4g,36mmol)和100mL N,N-二甲基甲酰胺,搅拌溶解。将反应溶液冷却至40℃,然后加入七钼酸铵四水合物(0.9g,0.72mmol)和间氯过氧苯甲酸(24.8g,144mmol),将反应混合物在40℃下进行反应。反应结束后,将反应混合物升温至20℃,加入50mL N,N-二甲基甲酰胺和100mL饱和NaHCO3水溶液。分离有机相,用50mL饱和NaHCO3水溶液洗涤,用Na2SO4干燥后,浓缩有机相,再用异丙醇重结晶,得到化合物III-3,收率87.9%,纯度99.1%。Add compound IV-3 (8.4g, 36mmol) and 100mL N,N-dimethylformamide to the reaction vessel, stir and dissolve. The reaction solution was cooled to 40°C, then ammonium heptamolybdate tetrahydrate (0.9g, 0.72mmol) and m-chloroperoxybenzoic acid (24.8g, 144mmol) were added, and the reaction mixture was reacted at 40°C. After the reaction is completed, the reaction mixture is heated to 20°C, and 50 mL of N,N-dimethylformamide and 100 mL of saturated NaHCO 3 aqueous solution are added. Separate the organic phase, wash with 50 mL saturated NaHCO 3 aqueous solution, dry with Na 2 SO 4 , concentrate the organic phase, and recrystallize with isopropyl alcohol to obtain compound III-3 with a yield of 87.9% and a purity of 99.1%.
实施例4Example 4
(1)制备物料A溶液:将化合物II(30g,92mmol)加入到四氢呋喃中,稀释至100mL,搅拌均匀,置于原料罐A(该原料罐底部通过阀门与微通道反应器相应的进料管道相连)中,氮气保护待用。(1) Prepare material A solution: Add compound II (30g, 92mmol) to tetrahydrofuran, dilute to 100mL, stir evenly, and place it in raw material tank A (the bottom of the raw material tank is connected to the feed pipe corresponding to the microchannel reactor through a valve connected), protected by nitrogen for later use.
(2)制备物料B溶液:将化合物III-1(32.6g,105mmol)加入到四氢呋喃中,稀释至150mL,搅拌均匀,置于原料罐B(该原料罐底部通过阀门与微通道反应器相应的进料管道相连)中,氮气保护待用。(2) Prepare material B solution: Add compound III-1 (32.6g, 105mmol) to tetrahydrofuran, dilute to 150mL, stir evenly, and place it in raw material tank B (the bottom of the raw material tank is connected to the microchannel reactor through a valve. The feed pipe is connected), and nitrogen protection is set aside for use.
(3)制备物料C溶液:将LiHMDS(20.2g,120mmol)加入到四氢呋喃中,稀释至80mL,搅拌均匀,置于原料罐C(该原料罐底部通过阀门与微通道反应器相应的进料管道相连)中,氮气保护待用。(3) Prepare material C solution: Add LiHMDS (20.2g, 120mmol) to tetrahydrofuran, dilute to 80mL, stir evenly, and place it in raw material tank C (the bottom of the raw material tank is connected to the feed pipe corresponding to the microchannel reactor through a valve connected), protected by nitrogen for later use.
(4)打开原料罐底部的阀门,通过进料泵分别输送原料罐A中物料A溶液、原料罐B中物料B溶液和原料罐C中物料C溶液,通过计数泵设定原料罐A的流速5ml/min,原料罐B的流速7.5ml/min,原料罐C的流速4ml/min,然后设定换热器的温度为-70℃,通道内保持反应时间为180s。反应结束后,从微通道反应器出口处接样,获得含有目标化合物I的混合物。(4) Open the valve at the bottom of the raw material tank, and transport the material A solution in raw material tank A, the material B solution in raw material tank B, and the material C solution in raw material tank C through the feed pump, and set the flow rate of raw material tank A through the counting pump. 5ml/min, the flow rate of raw material tank B is 7.5ml/min, the flow rate of raw material tank C is 4ml/min, then set the temperature of the heat exchanger to -70°C, and maintain the reaction time in the channel to 180s. After the reaction is completed, a sample is taken from the outlet of the microchannel reactor to obtain a mixture containing the target compound I.
将混合物升温至-10℃,用100mL 10%NaHCO3水溶液将反应猝灭。分离各相,用100mL乙酸乙酯萃取水层,用100mL 5%Na2CO3水溶液洗涤合并的有机相,并在真空下浓缩。浓缩完成后加入甲醇重结晶,得到化合物I,收率95.8%,纯度99.6%。The mixture was warmed to -10 °C and the reaction was quenched with 100 mL of 10% aqueous NaHCO solution . The phases were separated, the aqueous layer was extracted with 100 mL of ethyl acetate, the combined organic phases were washed with 100 mL of 5% aqueous Na2CO3 solution and concentrated under vacuum . After the concentration was completed, methanol was added for recrystallization to obtain compound I with a yield of 95.8% and a purity of 99.6%.
实施例5Example 5
(1)制备物料A溶液:将化合物II(30g,92mmol)加入到甲苯中,稀释至100mL,搅拌均匀,置于原料罐A(该原料罐底部通过阀门与微通道反应器相应的进料管道相连)中,氮气保护待用。(1) Prepare material A solution: Add compound II (30g, 92mmol) to toluene, dilute to 100mL, stir evenly, and place it in raw material tank A (the bottom of the raw material tank is connected to the feed pipe corresponding to the microchannel reactor through a valve connected), protected by nitrogen for later use.
(2)制备物料B溶液:将化合物III-2(41.3g,138mmol)加入到甲苯中,稀释至150mL,搅拌均匀,置于原料罐B(该原料罐底部通过阀门与微通道反应器相应的进料管道相连)中,氮气保护待用。(2) Prepare material B solution: Add compound III-2 (41.3g, 138mmol) to toluene, dilute to 150mL, stir evenly, and place it in raw material tank B (the bottom of the raw material tank is connected to the microchannel reactor through a valve. The feed pipe is connected), and nitrogen protection is set aside for use.
(3)制备物料C溶液:将氢化钠(2.3g,95.8mmol)加入到甲苯中,稀释至80mL,搅拌均匀,置于原料罐C(该原料罐底部通过阀门与微通道反应器相应的进料管道相连)中,氮气保护待用。(3) Prepare material C solution: Add sodium hydride (2.3g, 95.8mmol) to toluene, dilute to 80mL, stir evenly, and place it in raw material tank C (the bottom of the raw material tank is connected to the microchannel reactor through a valve. (connected to the material pipeline), nitrogen protection is available for use.
(4)打开原料罐底部的阀门,通过进料泵分别输送原料罐A中物料A溶液、原料罐B中物料B溶液和原料罐C中物料C溶液,通过计数泵设定原料罐A的流速5ml/min,原料罐B的流速7.5ml/min,原料罐C的流速4ml/min,然后设定换热器的温度为-90℃,通道内保持反应时间为100s。反应结束后,从微通道反应器出口处接样,获得含有目标化合物I的混合物。(4) Open the valve at the bottom of the raw material tank, and transport the material A solution in raw material tank A, the material B solution in raw material tank B, and the material C solution in raw material tank C through the feed pump, and set the flow rate of raw material tank A through the counting pump. 5ml/min, the flow rate of raw material tank B is 7.5ml/min, the flow rate of raw material tank C is 4ml/min, then set the temperature of the heat exchanger to -90°C, and maintain the reaction time in the channel as 100s. After the reaction is completed, a sample is taken from the outlet of the microchannel reactor to obtain a mixture containing the target compound I.
将混合物升温至-10℃,用100mL 10%NaHCO3水溶液将反应猝灭。分离各相,用100mL乙酸乙酯萃取水层,用100mL 5%Na2CO3水溶液洗涤合并的有机相,并在真空下浓缩。浓缩完成后加入甲醇重结晶,得到化合物I,收率91.4%,纯度99.3%。The mixture was warmed to -10 °C and the reaction was quenched with 100 mL of 10% aqueous NaHCO solution . The phases were separated, the aqueous layer was extracted with 100 mL of ethyl acetate, the combined organic phases were washed with 100 mL of 5% aqueous Na2CO3 solution and concentrated under vacuum . After the concentration was completed, methanol was added for recrystallization to obtain compound I with a yield of 91.4% and a purity of 99.3%.
实施例6Example 6
(1)制备物料A溶液:将化合物II(30g,92mmol)加入到二氧六环中,稀释至100mL,搅拌均匀,置于原料罐A(该原料罐底部通过阀门与微通道反应器相应的进料管道相连)中,氮气保护待用。(1) Prepare material A solution: Add compound II (30g, 92mmol) to dioxane, dilute to 100mL, stir evenly, and place it in raw material tank A (the bottom of the raw material tank is connected to the microchannel reactor through a valve. The feed pipe is connected), and nitrogen protection is set aside for use.
(2)制备物料B溶液:将化合物III-3(24.4g,92.3mmol)加入到二氧六环中,稀释至150mL,搅拌均匀,置于原料罐B(该原料罐底部通过阀门与微通道反应器相应的进料管道相连)中,氮气保护待用。(2) Prepare material B solution: Add compound III-3 (24.4g, 92.3mmol) to dioxane, dilute to 150mL, stir evenly, and place it in raw material tank B (the bottom of the raw material tank passes through the valve and microchannel The corresponding feed pipes of the reactor are connected), and nitrogen protection is set aside.
(3)制备物料C溶液:将NaHMDS(25.3g,138mmol)加入到二氧六环中,稀释至80mL,搅拌均匀,置于原料罐C(该原料罐底部通过阀门与微通道反应器相应的进料管道相连)中,氮气保护待用。(3) Prepare material C solution: Add NaHMDS (25.3g, 138mmol) to dioxane, dilute to 80mL, stir evenly, and place it in raw material tank C (the bottom of the raw material tank is connected to the microchannel reactor through a valve. The feed pipe is connected), and nitrogen protection is set aside for use.
(4)打开原料罐底部的阀门,通过进料泵分别输送原料罐A中物料A溶液、原料罐B中物料B溶液和原料罐C中物料C溶液,通过计数泵设定原料罐A的流速5ml/min,原料罐B的流速7.5ml/min,原料罐C的流速4ml/min,然后设定换热器的温度为-60℃,通道内保持反应时间为260s。反应结束后,从微通道反应器出口处接样,获得含有目标化合物I的混合物。(4) Open the valve at the bottom of the raw material tank, and transport the material A solution in raw material tank A, the material B solution in raw material tank B, and the material C solution in raw material tank C through the feed pump, and set the flow rate of raw material tank A through the counting pump. 5ml/min, the flow rate of raw material tank B is 7.5ml/min, the flow rate of raw material tank C is 4ml/min, then set the temperature of the heat exchanger to -60°C, and maintain the reaction time in the channel to 260s. After the reaction is completed, a sample is taken from the outlet of the microchannel reactor to obtain a mixture containing the target compound I.
将混合物升温至-10℃,用100mL 10%NaHCO3水溶液将反应猝灭。分离各相,用100mL乙酸乙酯萃取水层,用100mL 5%Na2CO3水溶液洗涤合并的有机相,并在真空下浓缩。浓缩完成后加入甲醇重结晶,得到化合物I,收率90.7%,纯度99.4%。The mixture was warmed to -10 °C and the reaction was quenched with 100 mL of 10% aqueous NaHCO solution . The phases were separated, the aqueous layer was extracted with 100 mL of ethyl acetate, the combined organic phases were washed with 100 mL of 5% aqueous Na2CO3 solution and concentrated under vacuum . After the concentration was completed, methanol was added for recrystallization to obtain compound I with a yield of 90.7% and a purity of 99.4%.
以上所述是本发明的具体实施方式。应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也视为本发明的保护范围。The above are specific embodiments of the present invention. It should be pointed out that for those of ordinary skill in the art, several improvements and modifications can be made without departing from the principles of the present invention, and these improvements and modifications are also regarded as the protection scope of the present invention.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310947198.3A CN116969863A (en) | 2023-07-31 | 2023-07-31 | Method for preparing Sha Kuba curved intermediate by utilizing micro-channel method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310947198.3A CN116969863A (en) | 2023-07-31 | 2023-07-31 | Method for preparing Sha Kuba curved intermediate by utilizing micro-channel method |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116969863A true CN116969863A (en) | 2023-10-31 |
Family
ID=88472737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310947198.3A Pending CN116969863A (en) | 2023-07-31 | 2023-07-31 | Method for preparing Sha Kuba curved intermediate by utilizing micro-channel method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116969863A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117645555A (en) * | 2023-11-30 | 2024-03-05 | 南京欧信医药技术有限公司 | Method for synthesizing Sha Kuba curved intermediate by using continuous flow tubular reactor |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104058911A (en) * | 2014-07-10 | 2014-09-24 | 联化科技股份有限公司 | Method for preparing sulfoxide or sulfone by using micro-channel reactor |
CN106431993A (en) * | 2016-09-14 | 2017-02-22 | 重庆市碚圣医药科技股份有限公司 | Method for preparing LCZ-696 key intermediate |
CN108675943A (en) * | 2018-06-13 | 2018-10-19 | 常州亚邦制药有限公司 | The preparation method of one planting sand library Ba Qu key intermediates |
CN113754565A (en) * | 2021-11-09 | 2021-12-07 | 南京威凯尔生物医药科技有限公司 | Method for preparing Shakubaqu intermediate in continuous flow microreactor |
-
2023
- 2023-07-31 CN CN202310947198.3A patent/CN116969863A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104058911A (en) * | 2014-07-10 | 2014-09-24 | 联化科技股份有限公司 | Method for preparing sulfoxide or sulfone by using micro-channel reactor |
CN106431993A (en) * | 2016-09-14 | 2017-02-22 | 重庆市碚圣医药科技股份有限公司 | Method for preparing LCZ-696 key intermediate |
CN108675943A (en) * | 2018-06-13 | 2018-10-19 | 常州亚邦制药有限公司 | The preparation method of one planting sand library Ba Qu key intermediates |
CN113754565A (en) * | 2021-11-09 | 2021-12-07 | 南京威凯尔生物医药科技有限公司 | Method for preparing Shakubaqu intermediate in continuous flow microreactor |
Non-Patent Citations (2)
Title |
---|
RALPH NICHOLAS SALVATORE等: "A mild and highly convenient chemoselective alkylation of thiols using Cs2CO3–-TBAI", TETRAHEDRON LETTERS, vol. 46, 4 November 2005 (2005-11-04), pages 8931 - 8935 * |
WALEED M. HUSSEIN等: "Use of Ethyl (Benzothiazol-2-ylsulfonyl)acetate for Malonic Ester-type Syntheses of Carboxylic Acids and Esters", AUST. J. CHEM., vol. 67, 12 May 2014 (2014-05-12), pages 1222 - 1227 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117645555A (en) * | 2023-11-30 | 2024-03-05 | 南京欧信医药技术有限公司 | Method for synthesizing Sha Kuba curved intermediate by using continuous flow tubular reactor |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN116969863A (en) | Method for preparing Sha Kuba curved intermediate by utilizing micro-channel method | |
CN106748921B (en) | A kind of virtue sulfuryl difluoroacetic acid salt compounds, preparation method and applications | |
WO2023201802A1 (en) | Synthesis method for ensitrelvir | |
CN104059001B (en) | A kind of adjacent benzoic preparation method of nitro sulfuryl | |
CN102775315A (en) | Preparation method of 3-aminophenylacetylene | |
CN102690194B (en) | Preparation method of 3-cyclopropylmethoxy-4-difluoromethoxy-benzoic acid | |
CN106188040A (en) | A kind of Fevipiprant and the preparation method of intermediate thereof | |
CN109553532B (en) | Preparation method of 4-bromoacetyl-2-methyl benzoic acid methyl ester | |
CN102295552B (en) | Method for increasing yield of 3,6-dichloro-2-hydroxybenzoic acid | |
CN116969862A (en) | A kind of synthesis method of sacubitril drug intermediate | |
CA2855021A1 (en) | Process for the preparation of roflumilast | |
CN107903209B (en) | Synthetic method of 2-amino-5-fluoropyridine-3-methyl formate | |
CN105085163A (en) | Synthesis method of 2-bromo-9,9-diphenylfluorene | |
CN107513056B (en) | A kind of synthetic method of quinoline compound containing tetrahydrofuran group | |
CN108484518A (en) | A kind of 2-(2,4,6- trimethylbenzene selenos)- 5- methylbenzoxazoles compound and preparation method | |
CN115286491A (en) | A kind of preparation method of 2-[2-(6-bromohexyloxy)ethoxymethyl]-1,3-dichlorobenzene | |
CN115611726A (en) | A method for nitrous compounds to participate in ring opening of cyclic ketones | |
CN106316824A (en) | Novel 2-fluorocyclopropane carboxylic acid synthesis method | |
CN100363320C (en) | Method for producing aromatic aldehyde | |
CN116332861B (en) | Preparation method of N- (3-methylpyrazine-2-) methyltrifluoroacetamide | |
CN115819348B (en) | A process for preparing N-aryl pyrazole compounds | |
CN119591560B (en) | Synthesis method of thifluzamide | |
CN104628555B (en) | A kind of synthetic method of pharmaceutical intermediate 4-(4-chlorphenyl) cyclohexyl-1-formic acid | |
CN117304076B (en) | Preparation method of N-sulfonyl amidine compound | |
CN115650851A (en) | A kind of preparation method of 2-fluoro-4-bromo-6-methylbenzoate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |